EP. 1: Off-Label Communications: What It Means for Stakeholders
Watch
EP. 2: Evidence From Drug Manufacturers and Patient Access
EP. 3: Considerations With Off-Label Communication
EP. 4: Off-Label Communications to Inform Formulary Management
EP. 5: Improving the Drug Approval Process to Reduce Drug Costs
EP. 6: Drug Price Negotiation by CMS
EP. 7: FDA Center of Excellence and the Drug Approval Process
EP. 8: Center of Excellence: Streamlining Drug Approvals
EP. 9: Empowering Stakeholders with Innovative Trial Designs
EP. 10: Drug Price Arguments Have No Easy Answer
EP. 11: What Will Patients Gain From the TAPUR Study?
EP. 12: Engaging Patients in Oncology Trials Is a Team Effort
EP. 13: Genomic Testing for Trial Participation and Access
EP. 14: Standardization of Biopsy Testing and Interpreting Data
EP. 15: Keeping Oncology Care Patient-Centered
EP. 16: Realizing Patient Goals in Cancer Care
EP. 17: Capturing Meaningful Measures in Cancer
EP. 18: Developing Appropriate Quality Measures in Oncology
EP. 19: Using Reimbursement Models to Overcome Oncology Care Gaps
EP. 20: Influence of Value Frameworks in Clinical Practice
EP. 21: ACA: Effect on Patients With Chronic Conditions
EP. 22: ACA, Medicaid Expansion, and Cancer Care
EP. 23: Role of Health Plans in Medicaid Expansion
EP. 24: The Balancing Act of Cost vs Access to Care
EP. 25: Navigating Eligibility and Access Issues When Diagnosed
EP. 26: The Politics of Healthcare Reform
EP. 27: How Will an ACA Repeal Affect Healthcare?
EP. 28: The Future of Healthcare in the United States
